WO2003029475A1 - Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope - Google Patents

Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope Download PDF

Info

Publication number
WO2003029475A1
WO2003029475A1 PCT/JP2002/009697 JP0209697W WO03029475A1 WO 2003029475 A1 WO2003029475 A1 WO 2003029475A1 JP 0209697 W JP0209697 W JP 0209697W WO 03029475 A1 WO03029475 A1 WO 03029475A1
Authority
WO
WIPO (PCT)
Prior art keywords
bound
epitope
vector
cells
mammalian cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/009697
Other languages
English (en)
French (fr)
Inventor
Aikichi Iwamoto
Ai Tachikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Priority to EP02770209A priority Critical patent/EP1447451A4/en
Priority to KR10-2004-7004307A priority patent/KR20040040475A/ko
Priority to US10/489,386 priority patent/US20040265272A1/en
Priority to CA002462259A priority patent/CA2462259A1/en
Priority to JP2003532688A priority patent/JPWO2003029475A1/ja
Publication of WO2003029475A1 publication Critical patent/WO2003029475A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2002/009697 2001-09-28 2002-09-20 Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope Ceased WO2003029475A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02770209A EP1447451A4 (en) 2001-09-28 2002-09-20 MAMMALIAN INFECTIVE, EPITOPEED BETA2m CODING VIRUS VECTOR AND ITS USE
KR10-2004-7004307A KR20040040475A (ko) 2001-09-28 2002-09-20 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용
US10/489,386 US20040265272A1 (en) 2001-09-28 2002-09-20 Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
CA002462259A CA2462259A1 (en) 2001-09-28 2002-09-20 Mammalian cell-infecting virus vector encoding epitope-bound .beta.2m and utilization thereof
JP2003532688A JPWO2003029475A1 (ja) 2001-09-28 2002-09-20 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-301290 2001-09-28
JP2001301290 2001-09-28

Publications (1)

Publication Number Publication Date
WO2003029475A1 true WO2003029475A1 (fr) 2003-04-10

Family

ID=19121729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009697 Ceased WO2003029475A1 (fr) 2001-09-28 2002-09-20 Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope

Country Status (7)

Country Link
US (1) US20040265272A1 (ja)
EP (1) EP1447451A4 (ja)
JP (1) JPWO2003029475A1 (ja)
KR (1) KR20040040475A (ja)
CN (1) CN1596311A (ja)
CA (1) CA2462259A1 (ja)
WO (1) WO2003029475A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031380A1 (ja) * 2002-10-01 2004-04-15 Dnavec Research Inc. TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法
WO2005087269A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 腫瘍増殖を抑制する方法
WO2005094878A1 (ja) * 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
JP2008503214A (ja) * 2004-06-17 2008-02-07 ベックマン コールター インコーポレーティッド ミコバクテリウム・ツベルクローシスのエピトープ、およびその使用法
US7521043B2 (en) 2004-01-13 2009-04-21 Dnavec Research Inc. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
CN101006172B (zh) * 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
JP2017523789A (ja) * 2014-08-06 2017-08-24 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
US10787494B2 (en) 2018-03-28 2020-09-29 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854917B1 (ko) 2000-03-30 2008-08-27 가부시키가이샤 디나벡크 겐큐쇼 센다이바이러스 벡터를 사용한 ａｉｄｓ 바이러스 백신
US6596206B2 (en) * 2001-03-30 2003-07-22 Picoliter Inc. Generation of pharmaceutical agent particles using focused acoustic energy
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
JP4969444B2 (ja) * 2005-06-14 2012-07-04 ディナベック株式会社 抗体の作製方法
US20100167341A1 (en) * 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN109354626B (zh) * 2018-11-16 2021-06-18 福州迈新生物技术开发有限公司 抗MyoD1蛋白单克隆抗体、细胞系及其制备方法和应用
WO2021027758A1 (en) * 2019-08-13 2021-02-18 Cure Genetics Co., Ltd. Genetically engineered cells and uses thereof
CN121208340B (zh) * 2025-11-26 2026-03-13 南京农业大学三亚研究院 一种检测a群轮状病毒抗体的胶体金试纸条及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO2001018223A1 (en) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001057204A1 (en) * 2000-02-02 2001-08-09 Yasufumi Kaneda Virus envelope vector for gene transfer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
WO1999064597A1 (en) * 1998-06-10 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO2001018223A1 (en) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001057204A1 (en) * 2000-02-02 2001-08-09 Yasufumi Kaneda Virus envelope vector for gene transfer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
KATO A. ET AL.: "The paramyxovirus, sendai virus, V protein encodes a luxury function required for viral pathogenesis", EMBO J., vol. 16, no. 3, 1997, pages 578 - 587, XP000941467 *
RAMANI K. ET AL.: "Site-specific gene delivery in vivo through engineered Seandai viral envelopes", PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 11886 - 11890, XP002942034 *
See also references of EP1447451A4 *
TAFURO S. ET AL.: "Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2, fusion molecules", EUR. J. IMMUNOL., vol. 31, no. 2, February 2001 (2001-02-01), pages 440 - 449, XP002959839 *
TOSHITANI K. ET AL.: "Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes", PROC. NATL. ACAD. SCI. USA, vol. 93, no. 1, 1996, pages 236 - 240, XP002051157 *
UGER R.A. ET AL.: "Covalent linkage to beta 2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes", J. IMMUNOL., vol. 162, no. 10, 1999, pages 6024 - 6028, XP002959840 *
UGER R.A., BARBER B.H.: "Creating CTL targets with epitope-linked beta 2-microglobulin constructs", J. IMMUNOL., vol. 160, no. 4, 1998, pages 1598 - 1605, XP002115504 *
WHITE J. ET AL.: "Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma", J. IMMUNOL., vol. 162, no. 5, 1999, pages 2671 - 2676, XP002959841 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031380A1 (ja) * 2002-10-01 2004-04-15 Dnavec Research Inc. TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法
US7521043B2 (en) 2004-01-13 2009-04-21 Dnavec Research Inc. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
WO2005087269A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 腫瘍増殖を抑制する方法
WO2005094878A1 (ja) * 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
JP2008503214A (ja) * 2004-06-17 2008-02-07 ベックマン コールター インコーポレーティッド ミコバクテリウム・ツベルクローシスのエピトープ、およびその使用法
US8889118B2 (en) 2004-06-24 2014-11-18 Dna Vec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
CN101006172B (zh) * 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
JP2017523789A (ja) * 2014-08-06 2017-08-24 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
JP2021000084A (ja) * 2014-08-06 2021-01-07 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
JP7272663B2 (ja) 2014-08-06 2023-05-12 ユニバーシティー オブ マイアミ インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
US12084483B2 (en) 2014-08-06 2024-09-10 University Of Miami Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US10787494B2 (en) 2018-03-28 2020-09-29 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
US12202872B2 (en) 2018-03-28 2025-01-21 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Also Published As

Publication number Publication date
KR20040040475A (ko) 2004-05-12
JPWO2003029475A1 (ja) 2005-01-20
EP1447451A4 (en) 2006-06-07
CA2462259A1 (en) 2003-04-10
US20040265272A1 (en) 2004-12-30
EP1447451A1 (en) 2004-08-18
CN1596311A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
EP1447451A4 (en) MAMMALIAN INFECTIVE, EPITOPEED BETA2m CODING VIRUS VECTOR AND ITS USE
York et al. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance
Ollivier et al. Fmoc solid-phase synthesis of peptide thioesters using an intramolecular N, S-acyl shift
MXPA04004634A (es) Expresion policistronica de anticuerpos.
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
RU93055035A (ru) Способ направления (индукции) иммунного ответа, клетка, днк, вектор, способ лечения, антитело
WO2009039854A2 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
TR200301277T3 (tr) Laboratuar ortamında kopyalama/dönüştürme sistemi kullanarak peptidler üretmek için işlem. EP1319074
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
Lushova et al. B-lymphocyte subsets: functions and molecular markers
Vaz-Santiago et al. Ex vivo stimulation and expansion of both CD4+ and CD8+ T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65
ATE353906T1 (de) Cd27 ligand
EP0644894A1 (en) PEPTID FOR THE STIMULATION OF CYTOTOIC T LYMPHOCYTES SPECIFIC FOR HEPATITIS C VIRUS.
Otvos Jr et al. Coupling strategies in solid-phase synthesis of glycopeptides.
Dhall et al. HLAncPred: a method for predicting promiscuous non-classical HLA binding sites
Nagayama‐Hasegawa et al. Expression and function of DNAM‐1 on human B‐lineage cells
Adda-Bedia et al. Dynamic instability of brittle fracture
Mizukoshi et al. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies
DK0906304T3 (da) Fremgangsmåde til fremstilling af 3-isochromanon
He et al. Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes
Fatehi et al. Time-delayed model of autoimmune dynamics
MXPA05008231A (es) Vector de alta expresion para celulas animales.
CA2327434A1 (en) Dna immunization against chlamydia infection
Zehbe et al. Differential MHC class II component expression in HPV‐positive cervical cancer cells: Implication for immune surveillance
AU2003278213A1 (en) Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003532688

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047004307

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2462259

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002770209

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002823703X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10489386

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002770209

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002770209

Country of ref document: EP